Article info

Download PDFPDF

717 AMG 160, a prostate-specific membrane antigen (PSMA)-targeted BiTE® immuno-oncology therapy, is active in models of advanced prostate cancer that are resistant to radioligand therapy

Authors

Citation

Lueckerath K, Bailis J, Current K, et al
717 AMG 160, a prostate-specific membrane antigen (PSMA)-targeted BiTE® immuno-oncology therapy, is active in models of advanced prostate cancer that are resistant to radioligand therapy

Publication history

  • First published December 10, 2020.
Online issue publication 
December 10, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.